Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Regorafenib-resistant KIT mutants do not bind regorafenib
| Class:Id | FailedReaction:9669870 |
|---|
| _displayName | Regorafenib-resistant KIT mutants do not bind regorafenib |
|---|
| _doRelease | TRUE |
|---|
| _timestamp | 2020-05-27 10:51:52 |
|---|
| authored | [InstanceEdit:9681395] Rothfels, Karen, 2020-04-01 |
|---|
| compartment | [Compartment:876] plasma membrane |
|---|
| created | [InstanceEdit:9669872] Rothfels, Karen, 2019-12-03 |
|---|
| disease | [Disease:1500689] cancer |
|---|
| edited | [InstanceEdit:9686618] Rothfels, Karen, 2020-05-04 |
|---|
| entityFunctionalStatus | [EntityFunctionalStatus:9669871] loss_of_function of regorafenib-resistant KIT mutants [plasma membrane] |
|---|
| input | [DefinedSet:9669829] regorafenib-resistant KIT mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:9657514] regorafenib [cytosol] |
|---|
| isChimeric | FALSE |
|---|
| literatureReference | [LiteratureReference:9671308] A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
[LiteratureReference:9671407] Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model
[LiteratureReference:9669094] Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
[LiteratureReference:9680576] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
[LiteratureReference:9680560] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
[LiteratureReference:9669259] The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
[LiteratureReference:9671447] Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases |
|---|
| modified | [InstanceEdit:9671506] Rothfels, Karen, 2019-12-19
[InstanceEdit:9674496] Rothfels, Karen, 2020-01-13
[InstanceEdit:9679387] Rothfels, Karen, 2020-03-24
[InstanceEdit:9680616] Rothfels, Karen, 2020-03-27
[InstanceEdit:9681434] Rothfels, Karen, 2020-04-01
[InstanceEdit:9686298] Rothfels, Karen, 2020-04-29
[InstanceEdit:9690167] Rothfels, Karen, 2020-05-27
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08 |
|---|
| name | Regorafenib-resistant KIT mutants do not bind regorafenib |
|---|
| normalReaction |
|
|---|
| releaseDate | 2020-06-10 |
|---|
| reviewed | [InstanceEdit:9678239] Serrano, César, 2020-03-13
[InstanceEdit:9678232] García-Valverde, Alfonso, 2020-03-13
[InstanceEdit:9678237] Pilco-Janeta, Daniel, 2020-03-13 |
|---|
| reviewStatus | [ReviewStatus:9821382] five stars |
|---|
| species | [Species:48887] Homo sapiens |
|---|
| stableIdentifier | [StableIdentifier:9669873] R-HSA-9669870.2 |
|---|
| summation | [Summation:9671478] Regorafenib is used as a secondary therapeutic in cases of i... |
|---|
| (hasEvent) | [Pathway:9669929] Regorafenib-resistant KIT mutants [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Regorafenib-resistant KIT mutants do not bind regorafenib (9669870)
